Biodesix Inc. (BDSX)
BDSX trades on Nasdaq in Health Care, Medical Specialities. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$25.00
-2.72% on the day
Market cap
$263.8M
Micro cap
Revenue · 2025
$88.5M
+24.1% on 2024
Net income · 2025
-$35.3M
-39.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | BDSX on Nasdaq |
| Sector | Health Care |
| Industry | Medical Specialities |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001439725 |
| SEC industry code | Services-Medical Laboratories |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $88.5M |
| Net income | -$35.3M |
| Operating income | -$27.9M |
| Net margin | -39.9% |
| Operating margin | -31.5% |
| Revenue growth | +24.1% |
| Cash | $19.0M |
| Total assets | $87.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-06-01 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-04-09 |
Source: SEC EDGAR submissions feed, 597 recent filings. All filings on EDGAR.
Peers in Medical Specialities
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TLSI | TriSalus Life Sciences Inc. | $4.00 | -3.38% | $246.3M |
| XGN | Exagen Inc. | $8.48 | +2.79% | $205.4M |
| YDES | YD Bio Limited | $6.10 | -3.63% | $432.1M |
| BNR | Burning Rock Biotech Limited | $15.00 | 0.00% | $158.2M |
| FLGT | Fulgent Genetics Inc. | $21.06 | -1.91% | $579.5M |
| KEQU | Kewaunee Scientific Corporation | $32.20 | -0.62% | $93.2M |
| SERA | Sera Prognostics Inc. | $2.04 | -1.45% | $80.5M |
| CSTL | Castle Biosciences Inc. | $32.88 | +0.37% | $1.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier